HLB Group said on the 2nd that Chair Jin Yang-gon recently bought shares of affiliates HLB Therapeutics and HLB Genex on the open market.
Jin bought 10,974 shares of HLB Therapeutics on the 29th last month and purchased an additional 25,000 shares on the 1st this month. On the same day, Jin also bought 14,000 shares of HLB Genex on the open market. As a result, Jin's holdings increased to 291,692 shares of HLB Therapeutics and 615,695 shares of HLB Genex.
HLB Group is currently awaiting U.S. Food and Drug Administration (FDA) decisions on the liver cancer first-line combination therapy of Rivoceranib and Camrelizumab, and on the bile duct cancer second-line therapy riphatugratinib. HLB Therapeutics is preparing to announce global phase 3 (SEER-2) results for the neurotrophic keratitis (NK) treatment candidate "RGN-259," and HLB Genex is working to expand catalase sales and enter the North American market.
Jin has recently visited major domestic securities firm branches to hold a relay investor relations (IR) roadshow, stepping up efforts to communicate with the market.
A group official said, "Jin's direct purchase of affiliate shares reflects confidence in the growth potential of key pipelines and major affiliates, as well as a commitment to responsible management."